{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-002599","form_type":"8-K","ticker":"FENC","cik":"0001211583","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2025-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.114660+00:00","generated_at":"2026-05-25T00:52:25.280744+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Fennec Pharma reports FY2024 PEDMARK sales $29.6M (+40% YoY); Q4 EBITDA loss $0.6M, cash $26.6M","bullets":["FY2024 net product sales $29.6M, up 40% from $21.3M in 2023; net loss narrowed to $0.07M from $16.0M.","Q4 2024 product sales $7.9M (+13% QoQ); EBITDA loss $0.6M; cash $26.6M at Dec 31, 2024.","Early repaid $13M of ~$32M convertible debt, saving ~$1.5M annual interest; reduces potential dilution.","Full-year operating income $2.6M vs loss $12.8M in 2023; G&A declined QoQ after one-time CEO severance.","PEDMARQSI launched in UK and Germany; Japan trial results (STS-J01) expected H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-002599","json":"https://secwatch.observer/filing/0001558370-25-002599.json","markdown":"https://secwatch.observer/filing/0001558370-25-002599.md","text":"https://secwatch.observer/filing/0001558370-25-002599.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1211583/000155837025002599/0001558370-25-002599-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1211583/000155837025002599/fencf-20250310x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T00:52:25.280744+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}